Article

Enhanced detection of mutations in BRCA1 exon 11 using restriction endonuclease fingerprinting-single-strand conformation polymorphism.

Center for Molecular Medicine, Haukeland University Hospital, Bergen, Norway.
Journal of Molecular Medicine (Impact Factor: 4.77). 02/2000; 78(10):580-7. DOI: 10.1007/s001090000147
Source: PubMed

ABSTRACT A novel approach to mutation screening in the large exon 11 (comprising 3427 bp) of the human BRCA1 gene is presented. Restriction endonuclease fingerprinting single-strand conformation polymorphism (REF-SSCP) is based on repeated detection of DNA sequence variants in different restriction endonuclease fragments, and we evaluated the method using blood samples from 25 Norwegian patients with hereditary breast/ovarian cancer. We compared REF-SSCP to constant denaturant gel electrophoresis (CDGE) and to the protein truncation test (PTT). REF-SSCP detected 12 different DNA variants. Four of these were not detected by CDGE, and only one variant detected by CDGE was missed by REF-SSCP. PTT detected 4 of these 13 variants. REF-SSCP was subsequently applied to a second patient series (Swedish, n=20). A total of 14 different DNA variants were detected by REF-SSCP, 6 of which were truncating mutations (PTT detected only 4). Nonsense and frameshift mutations that are putative breast/ovarian cancer mutations, were detected in 7 of the 25 Norwegian and 9 of the 20 Swedish patients.

0 Bookmarks
 · 
54 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: An estimated 5 to 10% of all breast and ovarian cancer is attributable to inherited mutations in two highly penetrant autosomal dominant susceptibility genes, BRCA1 and BRCA2. BRCA1 confers higher risk of ovarian cancer and BRCA2 much higher risk of male breast cancer. With the exception of missense mutations in the RING finger near the amino terminus of BRCA1, virtually all germline mutations in the gene cause the novel BRCA1 protein to be prematurely truncated. Approximately 90% of breast tumors in BRCA1 families, 50% of unselected breast tumors and 65-80% of unselected ovarian tumors have lost one allele of BRCA1 by somatic deletion. Very few tumors have detectable somatic point mutations in BRCA1. Inhibition of BRCA1 expression in mammary epithelial cell lines also suggests that BRCA1 may act as a tumor suppressor. The biological function of BRCA1 is still unknown, although identification of a patient homozygous for an inherited BRCA1 mutation suggests that the gene's function may be essential only to specific tissues. At least two other genes, P53 and the androgen receptor, are responsible for inherited predisposition to breast cancer in rare families. Several epidemiologic studies suggest that individuals carrying rare alleles at a minisatellite flanking the HRAS locus are at increased risk of cancer, including breast cancer. Finally, preliminary epidemiologic studies also suggest that individuals heterozygous for mutations in the ataxia telangiectasia gene may be at increased risk of breast cancer.
    Human Molecular Genetics 02/1995; 4 Spec No:1811-7. · 7.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The breast cancer susceptibility gene on chromosome 17q, BRCA1, has now been isolated. Mutations in this gene have been detected in many families with a predisposition to breast cancer. Most of these mutations result in truncation and presumed inactivation of the BRCA1 protein. A large number of distinct mutations have been reported, although some families have identical mutations, probably due to a founder effect. Certain evidence suggests that mutations positioned towards the 5' end of the gene carry a higher risk of ovarian cancer than those at the 3' end. BRCA1 is infrequently somatically mutated in sporadic breast or ovarian cancer. The BRCA2 gene has been localized to chromosome 13q12-q13. BRCA2 carries a risk of breast cancer similar to that of BRCA1, but is associated with a lower risk of ovarian cancer and a higher risk of male breast cancer. Additional breast cancer susceptibility genes probably exist, but may be difficult to locate by conventional methods.
    Current Opinion in Genetics & Development 03/1996; 6(1):93-7. · 7.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BRCA1 and BRCA2 have now been isolated and a large number of families characterized for the presence of mutations in these breast cancer susceptibility genes. Data from these studies are beginning to provide us with answers to many important questions. It is clear that estimates of attributable risk and penetrance are dependent on the population being studied. For example, studies of large, extensively affected families suggest that 45% of inherited breast cancer is due to BRCA1 mutations, while similar studies in individuals ascertained from breast cancer risk evaluation clinics suggest that the attributable risk is only 15%-20%. Similarly the large families yield penetrance estimates of 87% by age 85, while a more population-based study suggests somewhat lower rates--60% by age 70. In addition, studies of BRCA1-related tumors suggest that there may be some important molecular differences as compared to sporadic tumors, with a predominance of high grade lesions that are ER negative and an increased rate of p53 mutations. Controversy remains about the potential for genotype/phenotype correlation, and previous anecdotal reports of improved survival in families with familial breast cancer have yet to be fully evaluated. Finally, clinical recommendations are being formulated, with current recommendations centered on screening for breast cancer risk and prophylactic oophorectomy for presumed reduction of ovarian cancer risk.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 02/1998; 152:49-59.

Full-text (2 Sources)

Download
16 Downloads
Available from
May 23, 2014